Display options
Cite
Kusakawa K, Harada KH, Kagimura T, et al. Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). J Arrhythm. 2016;33(2):99-106doi: 10.1016/j.joa.2016.06.006.
Kusakawa, K., Harada, K. H., Kagimura, T., & Koizumi, A. (2017). Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). Journal of arrhythmia, 33(2), 99-106. https://doi.org/10.1016/j.joa.2016.06.006
Kusakawa, Koichi, et al. "Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study)." Journal of arrhythmia vol. 33,2 (2017): 99-106. doi: https://doi.org/10.1016/j.joa.2016.06.006
Kusakawa K, Harada KH, Kagimura T, Koizumi A. Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study). J Arrhythm. 2017 Apr;33(2):99-106. doi: 10.1016/j.joa.2016.06.006. Epub 2016 Aug 11. PMID: 28416974; PMCID: PMC5388034.
Copy Download .nbib Format: NLM
Share it on

J Arrhythm. 2017 Apr;33(2):99-106. doi: 10.1016/j.joa.2016.06.006. Epub 2016 Aug 11.

Major determinants for the selecting antithrombotic therapies in patients with nonvalvular atrial fibrillation in Japan (JAPAF study).

Journal of arrhythmia

Koichi Kusakawa, Kouji H Harada, Tatsuo Kagimura, Akio Koizumi

Affiliations

  1. Department of Health and Environmental Sciences, Kyoto University Graduate School of Medicine, Konoe-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan.
  2. Department of Statistical Analysis, Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, 1-5-4 Minatojima-minamimachi, Chuou-ku, Kobe 650-0047, Japan.

PMID: 28416974 PMCID: PMC5388034 DOI: 10.1016/j.joa.2016.06.006

Abstract

BACKGROUND: Oral anticoagulants (OACs) can help prevent stroke in patients with nonvalvular atrial fibrillation (NVAF). The aim of this study was to characterize the use of OACs other than direct thrombin inhibitors (DTIs) for NVAF.

METHODS: Patients with NVAF taking antithrombotics other than DTIs were enrolled in this cross-sectional study. Patient demographics and medication history were collected, and the patients were classified as taking antiplatelet monotherapy (AP), anticoagulant monotherapy (AC), or combination therapy (AP+AC). OAC users were also stratified as naïve (N; initiated within 6 months), switcher (S; switched within 6 months), or prevalent user (P; continued for >6 months).

RESULTS: A total of 3053 patients (AP, 216; AC, 2381; AP+AC, 456) from 268 sites were enrolled from 2012 to 2013. Significant differences were observed in CHADS

CONCLUSIONS: Patients taking AP+AC had higher CHADS

Keywords: Antiplatelet; Cross-sectional study; Nonvalvular atrial fibrillation; Oral anticoagulant

References

  1. Circ J. 2011;75(7):1539-47 - PubMed
  2. J Cardiol. 2013 Apr;61(4):260-6 - PubMed
  3. J Epidemiol. 2005 Sep;15(5):194-6 - PubMed
  4. Circ J. 2013;77(1):231-48 - PubMed
  5. Cerebrovasc Dis. 2004;18(1):47-56 - PubMed
  6. BMJ Open. 2013 May 03;3(5):null - PubMed
  7. Circulation. 1999 Jun 15;99(23):3028-35 - PubMed
  8. Circ J. 2008 Jun;72(6):909-13 - PubMed
  9. Nihon Rinsho. 2011 Nov;69 Suppl 9:567-71 - PubMed
  10. N Engl J Med. 2009 Sep 17;361(12):1139-51 - PubMed
  11. J Arrhythm. 2016 Apr;32(2):145-50 - PubMed
  12. Int J Cardiol. 2009 Oct 2;137(2):102-7 - PubMed
  13. Nephron. 1976;16(1):31-41 - PubMed
  14. Circ J. 2014;78(8):1997-2021 - PubMed
  15. Circulation. 1991 Aug;84(2):527-39 - PubMed
  16. Stroke. 2008 Jun;39(6):1740-5 - PubMed
  17. Lancet. 2007 Aug 11;370(9586):493-503 - PubMed
  18. Stroke. 1991 Aug;22(8):983-8 - PubMed
  19. J Cardiol. 2015 Mar;65(3):175-7 - PubMed
  20. Arch Intern Med. 1998 Jul 27;158(14):1513-21 - PubMed
  21. N Engl J Med. 2011 Sep 8;365(10):883-91 - PubMed
  22. Am J Med. 2014 Apr;127(4):329-336.e4 - PubMed

Publication Types